CP, a more potent and specific NHE inhibitor than AM, protects neurons from apoptosis, attenuates glutamate-mediated mitochondrial death pathways, as well as decreases the cellular entry of Ca++ and the mitochondrial overloading of ROS. Thus, NHE1 inhibition may prevent neural necrosis and apoptosis. CP has also been advised to be considered in cancer treatment. Here, SLC9C1 is linked to cancer.